xenon xe-133
Approved
Oct 10, 1974
XENON XE-133 (Xenon-133) is an isotope of xenon. It is a radionuclide that is inhaled to assess pulmonary function, and to image the lungs. It is also used to image blood flow, particularly in the brain. Xenon Xe 133 diffuses easily, passing through cell membranes and exchanging freely between blood and tissue. It is distributed in the lungs in a manner similar to that of air, thus representing the regions of the lung that are aerated. The gamma photons of xenon Xe 133 can then be employed to obtain counts per minute per lung or region of the lung, or to display their distribution as a scan. Scintigraphs taken during the washout period, as the patient breathes room air, will show any obstruction in the airways as regions of radioactive gas trapping or retention. (In the presence of an abnormal or near normal Tc 99m albumin aggregated perfusion study, a normal ventilation study favors a diagnosis of pulmonary emboli. However, the presence of xenon Xe 133 gas trapping, during washout imaging, in areas of abnormal perfusion, favors a diagnosis of chronic-type obstructive pulmonary disease.) — NCATS
Clinical trial activity
37 trials · 40 clinical orgs · 4 marketing orgs
Earliest trial started Mar 1, 2004 (NCT00192959)
Timeline
1970s
- Oct 10, 1974
Lantheus Medical Imaging — Earliest FDA Approval
- Oct 10, 1974
Lantheus Medical Imaging — NDA Secondary Org
- Oct 10, 1974
Lantheus Medical Imaging — NDA Organization
- Nov 16, 1976
General Electric — NDA Secondary Org
1980s
- Mar 9, 1982
Mallinckrodt — NDA Secondary Org
- Mar 9, 1982
Curium Pharma — NDA Secondary Org
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Acute Febrile Encephalopathy · Phase 2
- Allergy and Immunology · Phase 3
- Anesthesia · Phase 4
- Anesthetics, Inhalation · Phase 3
- Asthma · Phase 2
- Brain Injuries · Phase 2
- Cognition Disorders · Phase 2
- Colorectal Neoplasms · Phase 2
- Coronary Artery Bypass · Phase 3
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 3
- Delirium · Phase 2
- General Surgery · Phase 3
- Healthy Volunteers · Phase 3
- Heart Diseases · Phase 3
- Hemodynamics · Phase 4
- Hypothermia · Phase 2
- Kidney Diseases · Phase 3
- Lung · Phase 3
- Lung Diseases · Phase 2
- Lung Diseases, Interstitial · Phase 1
- Obesity · Phase 4
- Obsessive-Compulsive Disorder · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Post-Cardiac Arrest Syndrome · Phase 3
- Postoperative Complications · Phase 3
- Postoperative Nausea and Vomiting · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Pulmonary Embolism · Phase 3
- Pulmonary Surgical Procedures · Phase 3
- Sevoflurane · Phase 3
- Sympathetic Nervous System · Phase 1
- Xenon · Phase 3
Mechanism of action
- LungBINDING AGENT
Lung binding agent
- Unspecified targetOTHER
Diagnostic agent
Approval history
- approvedOct 10, 1974
Chemistry & pharmacology
SMILES
[133Xe]- Mol. weight
- 132.90590566 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
- Imaging
- 133-xenon
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- NCATSX3P9A5HNYF ↗
- ChEMBLCHEMBL1236802 ↗
- ChEMBLCHEMBL1200685 ↗
Also known as
- 133xe
- 133xe
- xe 133
- xe-133
- xe-133
- xeneisol
- xeneisol
- xenon
- xenon
- xenon
- xenon
- xenon
- xenon
- xenon
- xenon-133
- xenon-133
- xenon-133
- xenon-133
- xenon (133 xe)
- xenon (133 xe)
- xenon (133xe)
- xenon (133xe)
- xenon (133xe) gas
- xenon (133xe) gas
- xenon (133xe) gas
- xenon (133xe) gas
- xenon (133xe) gas
- xenon (133xe) injection
- xenon (133xe) injection
- xenon (133xe) v.s.s.
- xenon xe 133
- xenon xe 133
- xenon xe 133
- xenon xe 133
- xenon xe-133
- xenon xe-133
- xenon xe-133
- xenon xe-133
- xenon xe-133
- xenon, xe-133
- xenon, xe-133
- xenon xe 133 gas ampule
- xenon xe 133 gas vials
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03331302 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2018 | University of Virginia |
| NCT03418090 | Phase 3 | Aug 17, 2018 | Polarean Inc. |
| NCT03417687 | Phase 3 | Aug 17, 2018 | Polarean Inc. |
| NCT03176186 | Phase 3 | Oct 15, 2017 | NeuroproteXeon, Inc. |
| NCT03054870 | Phase 3 | Apr 1, 2017 | Certus International, Cyclomedica Australia PTY Limited |
| NCT02768727 | Phase 2 | Apr 1, 2016 | University of Pennsylvania |
| NCT02682758 | Phase 4 | Feb 1, 2016 | University of Duesseldorf |
| NCT02774096 | N/A | Feb 1, 2016 | Capital Medical University |
| NCT02468531 | N/A | Jan 1, 2015 | Capital Medical University |
| NCT02220426 | Phase 1 | Sep 1, 2014 | University of North Carolina at Chapel Hill |
| NCT02129400 | Phase 3 | May 1, 2014 | RWTH Aachen University |
| NCT02071394 | Phase 2 | Mar 1, 2014 | University of Bristol |
| NCT02098148 | Phase 2 | Nov 1, 2013 | Mclean Hospital |
| NCT01839084 | Phase 3 | Jul 1, 2013 | German Research Foundation, RWTH Aachen University |
| NCT01948765 | Phase 2 | Jun 1, 2013 | Katholieke Universiteit Leuven |
| NCT01832363 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), University of Virginia, Washington University in St. Louis, Xemed LLC |
| NCT01757106 | Phase 2 | Dec 1, 2012 | Katholieke Universiteit Leuven |
| NCT01696630 | Phase 2 | Oct 1, 2012 | Centre Leon Berard |
| NCT01458639 | Phase 3 | Aug 1, 2012 | Certus International, Columbia University, Cyclomedica Australia PTY Limited, Washington University in St. Louis |
| NCT01545271 | Phase 1/Phase 2 (Phase 2) | May 1, 2012 | University of Bristol |
Organizations
Research & Development (40)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Air Liquide | For profit | 7 | 6 | 4 | 2008 |
| RWTH Aachen University | Academic/Hospital | 6 | 5 | 3 | 2008 |
| University of Virginia | Academic/Hospital | 3 | 1 | 1 | 2011 |
| Capital Medical University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Centre Hospitalier Universitaire de Nīmes | Academic/Hospital | 2 | 2 | 2 | 2010 |
| Certus International | For profit | 2 | 0 | 1 | 2012 |
| Cyclomedica Australia PTY Limited | For profit | 2 | 2 | 1 | 2012 |
| German Research Foundation | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Katholieke Universiteit Leuven | Academic/Hospital | 2 | 2 | 1 | 2012 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2011 |
| Polarean Inc. | For profit | 2 | 2 | 1 | 2018 |
| University of Bristol | Academic/Hospital | 2 | 2 | 1 | 2012 |
| University of Duesseldorf | Academic/Hospital | 2 | 1 | 2 | 2010 |
| University of Paris | Academic/Hospital | 2 | 0 | 2 | 2009 |
| Washington University in St. Louis | Academic/Hospital | 2 | 0 | 2 | 2012 |
| Xemed LLC | For profit | 2 | 2 | 1 | 2011 |
| BIOMNIS | For profit | 1 | 0 | 1 | 2010 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2012 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Curium Pharma | For profit | NDA2 | Mar 9, 1982 |
| General Electric | For profit | NDA2 | Nov 16, 1976 |
| General Electric | For profit | SYN | Mar 24, 1976 |
| Lantheus Medical Imaging | For profit | NDA2 | Oct 10, 1974 |
| Lantheus Medical Imaging | For profit | NDA | Oct 10, 1974 |
| Mallinckrodt | For profit | NDA2 | Mar 9, 1982 |